CWC
VRTX icon

Carolinas Wealth Consulting’s Vertex Pharmaceuticals VRTX Stock Holding History

Carolinas Wealth Consulting’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59
Closed -$28.6K – 937
2025
Q1 		$28.6K Buy
59
+3
+5% +$1.4K 0.01% 411
2024
Q4 		$22.6K Hold
56
– – ﹤0.01% 458
2024
Q3 		$26K Sell
56
-1
-2% -$480 ﹤0.01% 449
2024
Q2 		$26.7K Sell
57
-56
-50% -$24.3K 0.01% 447
2024
Q1 		$47.2K Sell
113
-148
-57% -$62.6K 0.01% 384
2023
Q4 		$106K Buy
261
+56
+27% +$20.7K 0.02% 226
2023
Q3 		$74.2K Sell
205
-101
-33% -$35.3K 0.02% 257
2023
Q2 		$108K Buy
306
+75
+32% +$25.3K 0.02% 250
2023
Q1 		$72.8K Buy
231
+64
+38% +$19.2K 0.02% 304
2022
Q4 		$48.2K Sell
167
-17
-9% -$5.18K 0.01% 367
2022
Q3 		$53K Sell
184
-18
-9% -$5.18K 0.01% 318
2022
Q2 		$57K Sell
202
-49
-20% -$13.1K 0.01% 309
2022
Q1 		$66K Sell
251
-59
-19% -$14K 0.01% 315
2021
Q4 		$68K Hold
310
– – 0.01% 318
2021
Q3 		$56K Hold
310
– – 0.01% 328
2021
Q2 		$63K Hold
310
– – 0.01% 331
2021
Q1 		$67K Buy
310
+42
+16% +$9.22K 0.02% 320
2020
Q4 		$63K Buy
268
+131
+96% +$30.1K 0.02% 301
2020
Q3 		$37K Buy
137
+59
+76% +$16.3K 0.01% 320
2020
Q2 		$23K Buy
+78
New +$21.1K 0.01% 275

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Carolinas Wealth Consulting's VRTX Position: Q2 2025 in Review

Carolinas Wealth Consulting sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 59 shares — an estimated $28.6K sold.

Carolinas Wealth Consulting first reported a position in VRTX in Q2 2020 and held it in 20 quarters. The position peaked at $108K in Q2 2023. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Carolinas Wealth Consulting reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 59 Vertex Pharmaceuticals shares in Q2 2025, an estimated $28.6K.
  • Carolinas Wealth Consulting first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 20 quarters.
  • Carolinas Wealth Consulting's Vertex Pharmaceuticals position peaked at $108K in Q2 2023.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2025.